Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCX282-B for moderate to severe Crohn's disease
2005-003827-38Phase 2Completed
- Sponsor
- ChemoCentryx
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vercirnon in Crohn's disease (4 arms), sponsored by ChemoCentryx. Primary endpoint: Clinical response at Day 57. Started Nov 2005; status: completed.
02
Drugs
vercirnon
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2005-003827-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003827-38.